1. Home >
  2. M&A >
  3. Stake Purchase >
  4. United States >
  5. New Jersey >
  6. Aspire Capital Partners Invests In Scynexis

Investment Summary

Aspire Capital Partners Invests In Scynexis

On April 13, 2020, private equity firm Aspire Capital Partners invested in life science company Scynexis

Investment Highlights
  • This is Aspire Capital Partners’ 2nd transaction in the Life Science sector.
  • This is Aspire Capital Partners’ 1st transaction in the United States.
  • This is Aspire Capital Partners’ 1st transaction in New Jersey.

Investment Summary
Date 2020-04-13
Target Scynexis
Sector Life Science
Investor(s) Aspire Capital Partners
Deal Type Stake Purchase

Target

Scynexis

Jersey City, New Jersey, United States
Scynexis is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative therapies. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapeutic areas. Scynexis was formed in 2000 and is based in Jersey City, New Jersey.

Search 205,615 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Aspire Capital Partners

Investor

Category Private Equity Firm
Founded 2010
Size Small
Type Sector Focused
DESCRIPTION

Aspire Capital Partners LLC is an investment group that manages a long-only investment fund focused on making open market and direct equity investments in publicly traded companies. The Firm has a particular interest in the healthcare and technology sectors. Aspire Capital Partners LLC is based in Chicago, Illinois.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Stake Purchase) 2 of 2
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-09-27 Akari Therapeutics

London, New York, United Kingdom

Akari Therapeutics is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression. Akari Therapeutics is headquartered in London, United Kingdom.

Buy -
Mergr

Product

Company

Legal